About Harmony Biosciences
Harmony Biosciences is a company based in Plymouth Meeting (United States) founded in 2017. Harmony Biosciences has raised $345 million across 6 funding rounds from investors including Fidelity Investments, Orbimed and HBM Healthcare Investments. The company has 268 employees as of December 31, 2024. Harmony Biosciences has completed 1 acquisition, including Zynerba Pharma. Harmony Biosciences offers products and services including ZYN002. Harmony Biosciences operates in a competitive market with competitors including QurAlis, Passage Bio, Evox Therapeutics, MindMed and Relmada, among others.
- Headquarter Plymouth Meeting, United States
- Employees 268 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Harmony Biosciences Holdings, Inc.
-
Annual Revenue
$714.73 M (USD)22.8as on Dec 31, 2024
-
Net Profit
$145.49 M (USD)12.91as on Dec 31, 2024
-
EBITDA
$214.94 M (USD)-0.67as on Dec 31, 2024
-
Total Equity Funding
$345 M (USD)
in 6 rounds
-
Latest Funding Round
$200 M (USD), Debt – Conventional
Jan 27, 2020
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
268
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Harmony Biosciences
Harmony Biosciences is a publicly listed company on the NASDAQ with ticker symbol HRMY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Harmony Biosciences
Harmony Biosciences offers a comprehensive portfolio of products and services, including ZYN002.
Treatment for Fragile X Syndrome in neurological patients
People of Harmony Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
31 people
Operations Team
9 people
Finance and Accounting
7 people
Software Development Team
6 people
Product Management Team
5 people
Legal and Compliance
5 people
Human Resources and Administration
4 people
Sales and Marketing
3 people
Unlock access to complete
Funding Insights of Harmony Biosciences
Harmony Biosciences has successfully raised a total of $345M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $200 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Harmony Biosciences
Harmony Biosciences has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Orbimed and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked |
Investor details for Harmony Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Harmony Biosciences
Harmony Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zynerba Pharma.
Investment portfolio details for Harmony Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Transdermal cannabinoid therapies are developed for neurological disorders.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Harmony Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Harmony Biosciences
Detailed financials for Harmony Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Harmony Biosciences Comparisons
Peer comparison for Harmony Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Harmony Biosciences
Harmony Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QurAlis, Passage Bio, Evox Therapeutics, MindMed and Relmada, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Gene therapies for CNS rare diseases are developed.
|
|
| Locked | Locked | Locked |
Exosome-based gene therapies for neurological diseases are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Novel drug products for chronic pain treatment are developed.
|
Detailed competitors of Harmony Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Harmony Biosciences
Complete news archive for Harmony Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harmony Biosciences
Harmony Biosciences was founded in 2017.
Harmony Biosciences is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Harmony Biosciences is a funded company, having raised a total of $345M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Harmony Biosciences is 268.
Annual revenue of Harmony Biosciences is $714.73M as on Dec 31, 2024.
Developer of therapeutics for rare neurological diseases. The company is engaged in the research, development, and commercialization of novel treatments for rare diseases mainly CNS disorders including Wakix for Narcolepsy.
Harmony Biosciences's top competitors include QurAlis, MindMed and Passage Bio.
Harmony Biosciences offers ZYN002.
Yes, Harmony Biosciences is publicly traded on NASDAQ under the ticker symbol HRMY.
Harmony Biosciences has made 1 acquisition, including Zynerba Pharma.
Harmony Biosciences has 10 investors. Key investors include Fidelity Investments, Orbimed, HBM Healthcare Investments, CRG, and Aisling Capital.
The ticker symbol of Harmony Biosciences is HRMY on NASDAQ.